AmberGen, Inc. is a development-stage Proteomics Company based in Waltham, Massachusetts. Dr. Kenneth Rothschild founded the company to develop tools for drug discovery and diagnostic assays based on in-vitro protein expression, photo cleavable linkers and novel labeling techniques. Several products are under development from this platform technology. The Molecular Therapeutics Division in Waltham allows the technology to be applied to rapidly validate genes in disease associated pathways using a focused systems biology approach. This will enable novel drug targets to emerge whose biological functions are known, leading to the development of cell based assays for the screening of lead compounds. As part of this discovery, the mechanistic role of disease associated SNPs within these genes are being resolved in an effort to determine their effect on diversity and drug interactions. The Division is focused on asthma, osteoporosis and Alzheimer's disease. The ELISA-based protein truncation test, the first such assay that allows rapid automated mutation detection, is doing well in validation trials. Applications are in screening for colorectal cancer, breast cancer, and other diseases where the mutation results in a truncated protein. A sensitive, cost-effective and high throughput system for detecting drug-resistant strains of HIV-1 virus is based on our proprietary cell-free protein expression inventions and mass spectrometry. Our diagnostic assay for in-vitro detection of food and environmental allergies and detecting infectious pathogens in laboratory animals only requires drawing a small amount of blood because of its micro-array design. AmberGen's protein-protein micro-array combines cell-free methods for rapid expression of specially engineered protein libraries with advanced technology for micro-array fabrication and readout. The first such array is based on kinase proteins and has applications in detecting interactions to map critical cell signaling pathways in the areas of autoimmune and infectious diseases. Photo Cleavable Mass Tags facilitates mutation/SNP detection at the DNA level with multiplex mass spectrometry readout. Applications are in biomarkers for disease detection and treatment monitoring. Photo Cleavable Isotope Coded Affinity Tags when used in conjunction with mass spectrometry allows changes in the abundance of specific proteins in a complex mixture to be identified and monitored. AmberGen has invented reagents useful for rapid isolation and labeling of proteins and DNA (PC-biotins, PC-amidites and FluoroTect tRNAs). Certain kits are sold through Promega and Glen Research. Funding has been provided by the National Institutes of Health through their Small Business Innovation Research grant program. AmberGen has fourteen issued patents, some of which are licensed from Boston University.
Cadus Corporation is engaged in the development and application of yeast-based and other drug discovery technologies. The Company has a wholly owned subsidiary, Cadus Technologies, Inc. (the Subsidiary), which holds all applications, licenses and drug discovery technologies of the Company. Cadus and the Subsidiary have limited operations. The Company is seeking to license the Subsidiary’s drug discovery technologies; engage in joint ventures that will utilize the Subsidiary’s drug discovery technologies, and use a portion of their available cash to acquire or invest in companies or income producing assets. (Source: 10-K)
Mitotix, Incorporated is a biotechnology company engaged in the discovery and development of products to diagnose and treat cancer, opportunistic infections, and other cell proliferation disorders. The company's development programs are based on proprietary and patentable knowledge of the molecular pathways that regulate the cycle of cell growth and division. Mitotix recently formed major corporate collaborations in cancer therapeutics with The DuPont Merck Pharmaceutical Company focused on cyclin-dependent kinase inhibitors and with BASF Pharma focused on cdc25 inhibitors. Mitotix was founded in 1992 and is headquartered in Cambridge, Massachusetts.
EBI's primary target market is a group of disorders commonly known as the systemic inflammatory response syndrome ("SIRS"), including the clinical condition known as sepsis. Of the various inflammatory disorders, sepsis causes the greatest negative economic and medical consequences. It is the leading cause of death in hospital intensive care units worldwide, costing the US healthcare system an estimated $18 billion per year, and causing 1,400 deaths per day in the developed countries of the world. In SIRS/sepsis the body's immune system overreacts to an infection or other stress leading to severe organ damage and death. SIRS acts by triggering a series of chemical reactions in the body in a sequential, cascade,like process. In many cases, uncontrolled cascades result in death. The goal of the Company's therapeutic development initiative is to modulate the sequence of reactions in the immune cascade with patented small molecule sub-fractions of human hormones that attenuate an uncontrolled immune response. Our drug candidates have additional clinical applications involving similar inflammatory pathologies involved in radiation sickness, renal failure, avian flu and anthrax infections. EA-230 has completed Phase I single and multi-dose clinical trials including the Phase I expansion, LPS Proof of Concept, without material adverse reactions and the Company is currently preparing for Phase II clinical trials.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory